Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245748 · ClinicalTrials.gov registry record · Phase 4
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
A Phase 4 study of Depression and Anxious Depression, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT04245748: Recruiting Phase 4 study of Depression and Anxious Depression, sponsored by University of Cincinnati.
NCT04245748 is a Phase 4 study of Depression and Anxious Depression that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 84 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04245748, a Phase 4 study of Depression and Anxious Depression, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
Conditions Studied
Interventions
- DRUG Duloxetine
- DRUG Escitalopram
Study Locations (1)
Ohio
- University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
What NCT04245748 shows while recruiting
NCT04245748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Duloxetine is the first listed.
NCT04245748 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04245748 about?
NCT04245748 is a clinical study titled "Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)". Acute, double-blind, adaptively randomized treatment with duloxetine or escitalopram, followed by double-blind, randomized adjunctive treatment with clonazepam or pregabalin for persistent symptoms.
What is the current status of trial NCT04245748?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2020-03-01. Estimated completion is 2025-12-31.
What conditions does trial NCT04245748 study?
This clinical trial studies the following conditions: Depression, Anxious Depression.
What interventions are being tested in trial NCT04245748?
The interventions under investigation include: Duloxetine (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT04245748?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04245748 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04245748's enrollment target sits among peer trials
84 366th of 679 higher than 312 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy